Clinical trials: Metastatic Biliary Tract Carcinoma
Biliary Tract Cancer, Biliary Tract Neoplasms
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working.
- Conditions
- Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT07146646
- Testing
- Trifluridine/tipiracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Case Comprehensive Cancer Center
Biliary Tract Cancer
A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
This is a randomized, open-label, active-control, multi-center, phase IIb/III clinical study to evaluate the efficacy and safety of surufatinib vs.
- Trial name
- NCT03873532
- Testing
- Surufatinib, Capecitabine
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Hutchison Medipharma Limited
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic…
- Conditions
- Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- DUET-BTC (NCT07641036)
- Testing
- EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Metastatic Pancreatic Cancer, Metastatic Biliary Tract Cancer
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or BTC refractory or intolerant to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens to…
- Trial name
- CheckPAC (NCT02866383)
- Testing
- Nivolumab, Ipilimumab, Radiotherapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Herlev Hospital
Unresectable, Metastatic Biliary Tract Carcinoma
Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma
The purpose of this study is to determine whether Gemcitabine/Oxaliplatin (GEMOX) with or without Erlotinib (Tarceva) is effective in the treatment of unresectable, metastatic biliary tract carcinoma.
- Trial name
- NCT01149122
- Testing
- Gemcitabine/Oxaliplatin, Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- Samsung Medical Center
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where…
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic
- Trial name
- NCT05074472
- Testing
- ZB131
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- ZielBio, Inc.
Metastatic Cancer, Solid Tumor
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by…
- Trial name
- NCT04641871
- Testing
- Sym021, Sym022, Sym023
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 78 people
- Sponsor
- Symphogen A/S
Anal Cancer, Anxiety Disorder
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may…
- Conditions
- Anal Cancer, Anxiety Disorder, Breast Cancer, Depression
- Trial name
- NCT00896467
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Oscar Lambret
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
The objective of this study is to investigate the safety and tolerability of oral dose of selumetinib in combination with chemotherapies (cisplatin and gemcitabine) in Japanese patients with advanced biliary tract cancer (BTC).
- Trial name
- NCT01949870
- Testing
- Cisplatin, Gemcitabine, Selumetinib
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Biliary Tract Cancer
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma
- Trial name
- NCT02966821
- Testing
- Surufatinib
- Where
- 5 sites in China
- Volunteers
- 39 people
- Sponsor
- Hutchison Medipharma Limited
Biliary Tract Cancer
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing locally advanced or metastatic biliary tract cancer after…
- Trial name
- NCT07606599
- Testing
- BL-M07D1, Oxaliplatin, Calcium levofolinate
- Where
- 2 sites in China
- Volunteers
- 398 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Biliary Tract Cancer, Cholangiocarcinoma
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
This is a Phase 2 study to evaluate the efficacy, using objective response rate, of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous Tumor Infiltrating Lymphocytes (TIL) and high-dose…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms
- Trial name
- NCT03801083
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Udai Kammula
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
This phase I trial studies the side effects of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has…
- Conditions
- Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
- Trial name
- NCT05285358
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Trace Element Deficiency
Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers
The aim of the study is to determine the total concentration of selected trace elements (Cu, Zn, Fe), the proportion of free Cu and Cu bound to ceruloplasmin and the isotopic ratio of Cu65/Cu63 in blood serum samples from healthy…
- Trial name
- NCT06060990
- Testing
- trace elements
- Where
- Slovenia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute of Oncology Ljubljana